Zai Lab announces stoppage of Amgen’s gastric cancer trial

Zai Lab Limited announced on November 5, 2025, that Amgen, its partner and study sponsor, stopped the Phase 1b/3 FORTITUDE-102 trial. The trial was evaluating bemarituzumab plus chemotherapy and nivolumab for first-line gastric cancer patients. The decision to halt the trial was made due to inadequate efficacy, as determined by an ad hoc analysis requested by the data monitoring committee.

Zai Lab stated it would continue to work closely with Amgen and provide further updates as appropriate.

The board of directors of Zai Lab Limited includes Dr. Samantha Du as a director and Dr. John Diekman, Dr. Richard Gaynor, Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos, and Mr. Peter Wirth as independent directors. Dr. Samantha Du also serves as director, chairperson, and chief executive officer.